Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$46.27 USD

46.27
2,323,783

-0.45 (-0.96%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $46.30 +0.03 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI

by Zacks Equity Research

Quest Diagnostics' (DGX) joint study with the University of Alabama finds pregnant women undertested for STIs, raising serious concerns on maternal and newborn health.

Moumi Mondal headshot

Hologic (HOLX) Q3 Results Review: How to Play the Stock Now?

by Moumi Mondal

Hologic's (HOLX) performance in the third quarter of fiscal 2024 marks a return to growth, along with revenues and earnings beating estimates. Read on to find out what else the stock holds.

Here's Why Qiagen (QGEN) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Unlocking Qiagen (QGEN) International Revenues: Trends, Surprises, and Prospects

by Zacks Equity Research

Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash

by Zacks Equity Research

QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.

Compared to Estimates, Qiagen (QGEN) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Qiagen (QGEN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 5.77% and 0.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings

by Zacks Equity Research

Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.

Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Qiagen (QGEN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.

How to Play Henry Schein (HSIC) Ahead of Q2 Earnings?

by Zacks Equity Research

Henry Schein (HSIC) is expected to deliver impressive sales in both its businesses in the second quarter of 2024, along with a steady pace of recovery from the cyber incident.

Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note

by Zacks Equity Research

QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.

Moumi Mondal headshot

Pre Q3 Earnings: Is Hologic (HOLX) Stock a Portfolio Must-Have?

by Moumi Mondal

Hologic (HOLX) benefits from its unique set of businesses, each underpinned by its durable growth drivers. The impressive YTD price rally, earnings prowess and attractive valuation make the stock a top investment pick.

Qiagen (QGEN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Qiagen (QGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

QIAGEN (QGEN) Expands in NGS and FIGG With New Partnership

by Zacks Equity Research

QIAGEN (QGEN) announces a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance the identification of human remains of Indigenous people and African Americans.

Moumi Mondal headshot

Hologic (HOLX) Moves Up 2% in a Week: Time to Consider Buying?

by Moumi Mondal

Hologic's (HOLX) fundamental strength and cheaper valuation make it a great new addition to the portfolio.

QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test

by Zacks Equity Research

QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.

QIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions

by Zacks Equity Research

QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.

QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays

by Zacks Equity Research

QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.

QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform

by Zacks Equity Research

QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.

Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?

by Zacks Equity Research

Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu

by Zacks Equity Research

QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.